DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Sep 2020 Results of a substudy assessing whether Dapagliflozin treatment improves Left Ventricular myocardial longitudinal function and Left Ventricular diastolic function in patients with T2DM and LVH, presented at the ESC Congress 2020 Annual Congress of the European Society of Cardiology
24 Jun 2020 Results published in the European Heart Journal
18 Nov 2019 Primary endpoint (Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com